Key result
The HOMED-BP study is a 2x3 factorial randomized controlled trial designed to determine the optimal target home blood pressure and initial antihypertensive medication in 9,000 Japanese patients.
Why the study?
Does a specific target home blood pressure and choice of initial antihypertensive drug (calcium antagonist, ACE inhibitor, or ARB) reduce cardiovascular events in untreated essential hypertensive patients?
RCT (n=9,000)
PROBE (prospective randomized open-blinded endpoint)
2 x 3 factorial
Yes
Does a specific target home blood pressure and choice of initial antihypertensive drug (calcium antagonist, ACE inhibitor, or ARB) reduce cardiovascular events in untreated essential hypertensive patients?
The HOMED-BP study is a large-scale factorial RCT designed to determine the optimal target home blood pressure and initial antihypertensive drug class for Japanese patients.
No takes yet. Share an insight, caveat, or question.
Will inform optimal home BP targets and initial drug class in hypertension; extends randomized evidence to Japanese patients.
Fujiwara et al. (2002) conducted an RCT in Untreated essential hypertension (n=9,000). Target home BP (134-125/84-80 mmHg vs ≥125/80 mmHg) and initial drug (Ca-A, ACE-I, or ARB) vs. Factorial comparison was evaluated on Composite of non-fatal stroke, non-fatal myocardial infarction, and cardiovascular death. The HOMED-BP study is a 2x3 factorial randomized controlled trial designed to determine the optimal target home blood pressure and initial antihypertensive medication in 9,000 Japanese patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: